Want to see PRFX full AI Analyst Report?
PRFX Stock Chart & Stats
$0.80
-$0.27(-7.83%)
At close: 4:00 PM EST
$0.80
-$0.27(-7.83%)
Day’s Range― - ―
52-Week Range$1.23 - $17.94
Previous CloseN/A
Volume49.01K
Average Volume (3M)186.11K
Market Cap
$4.11M
Enterprise Value-$2.96M
Total Cash (Recent Filing)$4.14M
Total Debt (Recent Filing)$21.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-30.40
Shares Outstanding3,041,830
10 Day Avg. Volume213,091
30 Day Avg. Volume186,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)122.35
P/FCF Ratio-0.53
Enterprise Value/Market Cap-0.72
Enterprise Value/Revenue-173.82
Enterprise Value/Gross Profit55.76
Enterprise Value/Ebitda0.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-176.4
Revenue Forecast (FY)$10.31M
Bulls Say, Bears Say
Bulls Say
Product EfficacyPRF-110 was found to statistically significantly reduce pain over the first 48-hours.
Bears Say
Financial NeedsPainReform may need additional capital to complete necessary studies, but there are concerns about the ability to raise capital given current market conditions.
Market CompetitionThe recent approval of a generic version of Exparel, the market leader, impacts the market opportunity for PainReform's PRF-110.
PainReform News
PRFX FAQ
What was PainReform’s price range in the past 12 months?
PainReform lowest stock price was $1.23 and its highest was $17.94 in the past 12 months.
What is PainReform’s market cap?
PainReform’s market cap is $4.11M.
When is PainReform’s upcoming earnings report date?
PainReform’s upcoming earnings report date is Aug 19, 2026 which is in 35 days.
How were PainReform’s earnings last quarter?
Currently, no data Available
Is PainReform overvalued?
According to Wall Street analysts PainReform’s price is currently Overvalued.
Does PainReform pay dividends?
PainReform does not currently pay dividends.
What is PainReform’s EPS estimate?
PainReform’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainReform have?
PainReform has 3,041,830 shares outstanding.
What happened to PainReform’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PainReform?
Currently, no hedge funds are holding shares in PRFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PainReform
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
Technical Analysis
China Pharma Holdings
―
―
RedHill Biopharma
―
Cosmos Holdings
―
Shuttle Pharmaceuticals Holdings, Inc.
―